Journals / Genel Tıp Dergisi / 2022 / Cilt: 32 - Sayı: 5

Does Serum R-Spondin-1 Play a Role in PCOS Pathophysiology?

PCOS Patofizyolojisinde Serum R-Spondin-1'in Bir Rolü Var mıdır?

Pages
490–493
Publication Date
2022-10-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As compared to the control group, PCOS patients had significantly higher FGS, homeostasis model assessment of insulin resistance scores, Rspo1, and total testosterone levels (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Many new inflammatory and metabolic markers are considered to be involved in etiology of Polycystic ovary syndrome (PCOS).
📊
Key Findings & Data:R-spondin-1 (Rspo1) is a member of the roof plate-specific spondin protein family.
💡
Conclusion & Impact:As compared to the control group, PCOS patients had significantly higher FGS, homeostasis model assessment of insulin resistance scores, Rspo1, and total testosterone levels (p
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:R-spondin-1 · Polikistik over sendromu · Ferriman Gallwey skorları

Abstract

Objective: Many new inflammatory and metabolic markers are considered to be involved in etiology of Polycystic ovary syndrome (PCOS). R-spondin-1 (Rspo1) is a member of the roof plate-specific spondin protein family. Rspo1 levels have been associated with obesity and insulin resistance. We aimed to investigate whether Rspo1 has a role in the pathophysiology of PCOS. Materials and Methods: This cross-sectional study was planned with newly diagnosed and untreated PCOS cases and a control group without PCOS. Patients with PCOS and healty participants were compared for Rspo1 levels. In addition, the PCOS group was also grouped according to body mass index (BMI) and Ferriman Gallwey scores (FGS) and compared in terms of Rsop1 levels. Results: A total of 47 patients in the PCOS group and 36 participants in the control group, as total 83 participants were included in the study. PCOS and control groups had similar age and BMI. As compared to the control group, PCOS patients had significantly higher FGS, homeostasis model assessment of insulin resistance scores, Rspo1, and total testosterone levels (p

Özet

Amaç: Pek çok yeni inflamatuar ve metabolik belirtecin Polikistik Over Sendromu (PCOS) etiyolojisinde rol oynadığı düşünülmektedir. R-spondin-1 (Rspo1), tepe tabakaya özgü spondin protein ailesinin bir üyesidir. Rspo1 seviyeleri obezite ve insülin direnci ile ilişkilendirilmiştir. Rspo1'in PCOS patofizyolojisinde rolü olup olmadığını araştırmayı amaçladık. Gereç ve Yöntem: Bu kesitsel çalışma, yeni tanı konmuş ve tedavi edilmemiş PCOS olguları ve PCOS'u olmayan bir kontrol grubu ile planlandı. PCOS'lu hastalar ve sağlıklı katılımcılar, Rspo1 seviyeleri için karşılaştırıldı. Ayrıca PCOS grubu vücut kitle indeksi (VKİ) ve Ferriman Gallwey skorlarına (FGS) göre de gruplandırılarak Rsop1 düzeyleri açısından karşılaştırıldı. Bulgular: PCOS grubunda 47, kontrol grubunda 36 olmak üzere toplam 83 katılımcı çalışmaya dahil edildi. PCOS ve kontrol grupları benzer yaş ve VKİ'ye sahipti. Kontrol grubu ile karşılaştırıldığında, PCOS hastalarının FGS, insülin direnci skorlarının homeostaz modeli değerlendirmesi, Rspo1 ve toplam testosteron düzeyleri anlamlı olarak daha yüksekti (sırasıyla p

🔖

Cite This Article

BAŞPINAR, O., ŞİMŞEK, Y., KOÇER, D., DİZDAR, O. S., TOPALOĞLU, H. K. (2022). Does Serum R-Spondin-1 Play a Role in PCOS Pathophysiology?. Genel Tıp Dergisi, Cilt: 32 - Sayı: 5, 490–493. https://ajindex.com/articles/726153

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38. e25. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60(1):1-17.
  2. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-31.
  3. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26(2):251-82.
  4. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6):2453-5.
  5. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res. 2003;11(8):987-96. Frishman WH. Biologic markers as predictors of cardiovascular disease. Am J Med. 1998;104(6A):18S-27S. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24(3):278-301.
  6. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448-54.
  7. Usta A, Avci E, Bulbul CB, Kadi H, Adali E. The monocyte counts to HDL cholesterol ratio in obese and lean patients with polycystic ovary syndrome. Reprod Biol Endocrinol. 2018;16(1):34. Kim KA, Wagle M, Tran K, Zhan X, Dixon MA, Liu S, et al.R-Spondin family members regulate the Wnt pathway by a common mechanism. Mol Biol Cell. 2008;19(6):2588-96.
  8. Welters HJ, Kulkarni RN. Wnt signaling: relevance to beta-cell biology and diabetes. Trends Endocrinol Metab. 2008;19(10):349-55.
  9. Kang YE, Kim JM, Yi HS, Joung KH, Lee JH, Kim HJ, et al.Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance. Diabetes Metab J. 2019;43(3):368-76. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
  10. Hatch R, Rosenfield RL, Kim MH,